A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission
Naxitamab + GM-CSF is a good option to consolidate first CR of patients with HR-NB, including those who did not undergo autologous stem-cell transplantation. Efforts to prevent central nervous system relapse are warranted.
Authors
- Ellen M. Basu (ORCID: https://orcid.org/0000-0002-4555-220X)
- Audrey Mauguen (ORCID: https://orcid.org/0000-0003-3236-6093)
- Stephen S. Roberts (ORCID: https://orcid.org/0000-0001-8258-756X)
- Nai‐Kong V. Cheung (ORCID: https://orcid.org/0000-0001-6323-5171)
- Kim Kramer (ORCID: https://orcid.org/0000-0002-3803-878X)
- Brian H. Kushner (ORCID: https://orcid.org/0000-0002-8916-0697)
- Irene Y. Cheung (ORCID: https://orcid.org/0000-0002-1427-514X)
- Shakeel I. Modak (ORCID: https://orcid.org/0000-0002-7280-1726)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3427
- Citations
- 4
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.56